As such trials are designed, investigators should be mindful that the efficacy of competing IHC assays will evolve as independently informative markers are cherry-picked from omics discovery studies into more traditional pathology laboratory test formats.
OCM is the principal investigator, designed the investigation, collected the data, performed statistical analyses, and drafted the manuscript.
OM was a main investigator, designed the investigation, and was the main contributor to the preparation of the manuscript.
SWJ was the principal investigator, designed the investigation, and participated in data collection, statistical analysis and drafting of the manuscript.
Improvements in study design, investigator training and early proof-of-concept studies are being discussed as means to decrease failure rates and the duration of development.
For each type of study design, investigator needs to have some a priori information like precision, acceptable limits of α & β error, confidence level and effect size.
Methods: Two identically designed, randomized, investigator-blinded, multicenter trials were performed.
We designed an investigator-led, publicly funded, multicenter, randomized, 2 × 2 factorial, placebo-controlled, double-blind trial in four parallel groups.
The best trials are designed by investigators with burning questions to answer!
We therefore designed the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug- Resistant Hypertension (INSPiRED).
